When we divided kidney cancer patients into subgroups based on their gender, location of the primary tumour and tumour status, the gene expression level reacts similarly to general results; aggressive tumours have a significantly lower expression level of RGS5 (figure 4). This evidence concerns the gene RGS5 and neoplasm.